Pharma channel feed

Bay­er plans 95% cut to div­i­dend as part of CEO Bill An­der­son­'s turn­around project

Last year

Rick Gon­za­lez de­fend­ed Ab­b­Vie's em­pire. The next CEO will have to build a new one be­yond Hu­mi­ra

Last year
People

Mar­ket­ingRx roundup: Op­di­vo, Veozah on Peo­ple’s Choice Awards; AZ pub­lish­es new sus­tain­abil­i­ty re­port

Last year
Marketing

Take­da read­ies next phase in cor­po­rate and R&D cam­paign to help boost US pro­file

Last year
Marketing

Ab­b­Vie CEO Richard Gon­za­lez to re­tire Ju­ly 1 with Hu­mi­ra tran­si­tion un­der­way

Last year
People

The $100 bil­lion club gets a shake­up, dri­ven by biotech’s new blue-chip names

Last year
R&D

FDA ap­proves Io­vance's cell ther­a­py for melanoma, the first treat­ment based on tu­mor-in­fil­trat­ing lym­pho­cytes

Last year
Cell/Gene Tx
FDA+

Organon's Hu­mi­ra biosim­i­lar gets ex­clu­sive spot on VA for­mu­la­ry

Last year
FDA+

EMA pre­pares for changes to non-in­fe­ri­or­i­ty, equiv­a­lence study guid­ance

Last year
FDA+

FDA ex­pands la­bel for No­var­tis and Roche's block­buster, con­verts EMD Serono's NSCLC drug to full ap­proval

Last year
FDA+

As­traZeneca asks fed­er­al judge to de­cide in its fa­vor in drug price ne­go­ti­a­tions law­suit

Last year
Law

FDA goes af­ter web­sites mar­ket­ing 'u­nap­proved' semaglu­tide, tirzepatide

Last year
FDA+

Es­hoo calls out FDA for miss­ing dead­line on di­ver­si­ty ac­tion plan guid­ance

Last year
FDA+

GSK re­fresh­es ‘Shin­gles doesn’t care’ cam­paign with fo­cus on hard­er-to-reach groups

Last year
Marketing

Marks re­hash­es Covid-19 ap­proval time­line, de­fends vac­cines for chil­dren at hear­ing

Last year
FDA+

Pfiz­er could end Lip­i­tor an­titrust saga in­volv­ing Ran­baxy with $93M set­tle­ment

Last year
Law

Will slow up­take of Leqem­bi pose a risk to Bio­gen’s re­cov­ery?

Last year

Eicos Sci­ences wins FDA ap­proval for first se­vere frost­bite treat­ment

Last year
FDA+

Biden ad­min­is­tra­tion tar­gets GPOs, whole­salers in re­quest for in­for­ma­tion on gener­ic short­ages

Last year
FDA+

Ap­peals court sides with As­traZeneca, BMS, McKesson in saxagliptin heart fail­ure case

Last year
Law

Sage 'en­cour­aged' by ini­tial Zurzu­vae sales in post­par­tum de­pres­sion, but no word on ma­jor de­pres­sion plans

Last year

SEC, DOJ sub­poe­na Bio­gen over Aduhelm launch and for­eign busi­ness op­er­a­tions

Last year

In­cyte is 'op­ti­mistic' about skin dis­ease drug Opzelu­ra as pre­scrip­tions grow 77% in Q4

Last year

FDA ap­proves Ipsen’s Onivyde as first-line treat­ment for type of pan­cre­at­ic can­cer

Last year
FDA+
First page Previous page 70717273747576 Next page Last page
A service from the Financial Times